Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma

Blood

Volumn 125, Issue 13, 2015, Pages 2079-2086

  Sagiv Barfi, Idit ^a   Kohrt, Holbrook E ^a   Burckhardt, Laura ^a   Czerwinski, Debra K ^a   Levy, Ronald ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; IBRUTINIB; TOLL LIKE RECEPTOR 9; TUMOR ANTIGEN; CPG-OLIGONUCLEOTIDE; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYRIBONUCLEOTIDE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL SURVIVAL; CELL VIABILITY; COCULTURE; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG POTENTIATION; FEMALE; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; LYMPHOMA CELL; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL LINE; IMMUNOLOGY; INTRALESIONAL DRUG ADMINISTRATION; LYMPHOMA; RAT; SCID MOUSE; TRANSGENIC MOUSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL LINE; DRUG SYNERGISM; FEMALE; INJECTIONS, INTRALESIONAL; LYMPHOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; MICE, TRANSGENIC; OLIGODEOXYRIBONUCLEOTIDES; PYRAZOLES; PYRIMIDINES; RATS; TOLL-LIKE RECEPTOR 9;

EID: 84926170848     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-593137     Document Type: Conference Paper

References (26)

1. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20: 709-760.
2. Bauer S, Wagner H. Bacterial CpG-DNA licenses TLR9. Curr Top Microbiol Immunol. 2002;270: 145-154.
3. Li J, Song W, Czerwinski DK, et al. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007;179(4):2493-2500.
4. Houot R, Levy R. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood. 2009;113(15):3546-3552.
5. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107(29):13075-13080.
6. Satterthwaite AB, Witte ON. The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000;175:120-127.
7. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539-2549.
8. Sahu N, Venegas AM, Jankovic D, et al. Selective expression rather than specific function of Txk and Itk regulate Th1 and Th2 responses. J Immunol. 2008;181(9):6125-6131.
9. Cai Q, Westin J, Fu K, et al. Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol. 2014;93(4):541-546.
10. Alinari L, Christian B, Baiocchi RA. Novel targeted therapies for mantle cell lymphoma. Oncotarget. 2012;3(2):203-211.
11. Harrison C. Trial watch: BTK inhibitor shows positive results in B cell malignancies. Nat Rev Drug Discov. 2012;11(2):96.
12. Brown JR. Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials. Curr Hematol Malig Rep. 2013;8(1):1-6.
13. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
14. Akinleye A, Furqan M, Adekunle O. Ibrutinib and indolent B-cell lymphomas. Clin Lymphoma Myeloma Leuk. 2014;14(4):253-260.
15. Kosaka Y, Felices M, Berg LJ. Itk and Th2 responses: action but no reaction. Trends Immunol. 2006;27(10):453-460.
16. Minard-Colin V, Xiu Y, Poe JC, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood. 2008; 112(4):1205-1213.
17. Goldstein MJ, Varghese B, Brody JD, et al. A CpG-loaded tumor cell vaccine induces antitumor CD41 T cells that are effective in adoptive therapy for large and established tumors. Blood. 2011;117(1):118-127.
18. Rushworth SA, Murray MY, Zaitseva L, Bowles KM, Macewan DJ. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood. 2014;123(8):1229-1238.
19. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287-6296.
20. Sagiv-Barfi I, Kohrt HEK, Czerwinski DK, Ng PP, Chang BY, Levy R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by Ibrutinib, an inhibitor of both BTK and ITK [published online ahead of print February 17, 2015]. Proc Natl Acad Sci USA. doi:10.1073/ pnas.1500712112.
21. Doyle SL, Jefferies CA, Feighery C, O'Neill LA. Signaling by toll-like receptors 8 and 9 requires Bruton's tyrosine kinase. J Biol Chem. 2007; 282(51):36953-36960.
22. Kawakami Y, Inagaki N, Salek-Ardakani S, et al. Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3. Proc Natl Acad Sci USA. 2006;103(1): 153-158.
23. Goldenberg MM. Pharmaceutical approval update. P T. 2014;39(4):262-296.
24. Goldenberg MM. Pharmaceutical approval update. P T. 2014;39(1):37-39.
25. Marabelle A, Kohrt H, Sagiv-Barfi I, et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest. 2013;123(6):2447-2463.
26. Kolstad A, Kumari S, Walczak M, et al. Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. Blood. 2015; 125(1):82-89.